Baxter touts blood purification efficiency in EBP studies

Baxter (NYSE:BAX) today released data from 2 studies on extracorporeal blood purification studies, touting the blood purification method’s ability to remove harmful molecules linked to inflammation.

Extracorporeal blood purification takes place outside the body, with blood passing through a membrane within an extracorporeal circuit to filter harmful molecules and waste products out of the blood, the company said. The clean blood is then returned to the body. The method is commonly used for patients with kidney injuries.

Data from the studies was presented at the American Society of Nephrology’s annual Kidney Week in Chicago.

”Baxter continues to build on its commitment to contribute meaningful research to advance acute and chronic blood therapies. This exploratory research adds to the body of knowledge in an important area that is not fully understood – the treatment of inflammation-related conditions in chronic kidney disease and critically ill ICU patients,” medical affairs veep Dr. Dheerendra Kommala said in a prepared statement.

The 1st in vitro study examined EBP’s ability to remove inflammatory and auto-immune response stimulating cytokines, including IL-6, looking to reduce inflammation in end-stage renal disease patients, which can lead to complications such as cardiovascular disease.

Data from the study indicated that the EBP membranes were able to remove IL-6 and other cell activating molecules, with more porous mid-cut off and high-cut off membranes removing the molecules at a higher rate.

The 2nd in vitro study examined the efficiency of 2 different classes of membranes, a high-flux dialyzer and a high-cut off dialyzer, at removing 4 mid-sized molecules that could affect a range of biological functions, including inflammation and cardiovascular function.

Baxter said that after simulating treatment with each dialyzer, the high-cut off membrane proved to be more efficient at removal of the molecules, while the high-flux membrane did not remove the molecules at a rate that is required in acute care.

”While our findings conclude that targeting these molecules is possible, further research will help us understand the clinical impact of removing these molecules from the blood,” study author and senior R&D manager Markus Storr said in a press release.

Yesterday, Baxter released data on its Sharesource remote patient monitoring and home-use Amia automated peritonial dialysis systems, touting its ability to improve early detection of adverse issue issues and faster treatment.

Data on the platforms was presented at the American Society of Nephrology’s annual Kidney Week meeting last week in Chicago.

Data from a case study of Baxter’s Sharesource indicated that the system was able to identify a displaced catheter through an early alert and diagnosis, which was surgically repositioned, the company said.

The post Baxter touts blood purification efficiency in EBP studies appeared first on MassDevice.

from MassDevice http://ift.tt/2gdp2Z8